Shares of Dogwood Therapeutics Inc. (DWTX), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, are up more than 50% at $2.94 in premarket trading Tuesday.
The company's pipeline includes Halneuron for chemotherapy-induced neuropathic pain; IMC-1 for the treatment of fibromyalgia; and IMC-2 to treat Long COVID sequelae.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com